Administrative

拟议的加州大学旧金山分校自身免疫卓越中心(ACE)的行政单位包括 在NIH中心拨款管理方面有丰富经验的人员。校长 调查员David Wofsy博士在本周期担任加州大学旧金山分校ACE赠款的PI；在此之前 为此，他在加州大学旧金山分校的多功能关节炎和肌肉骨骼疾病中心担任了10年的PI (MAMDC)通过NIAMS提供赠款。因此，他在领导多个项目的NIH方面非常有经验 程序。沃夫西博士将负责监督加州大学旧金山分校中心，并将担任临床 加州大学旧金山分校到ACE项目的研究代表。杰弗里·布鲁斯通博士，行政部门联席PI 在管理复杂的计划拨款方面也有丰富的经验，这一点从他的 担任NIAID免疫耐受网络主任。蓝石博士将担任基础研究 加州大学旧金山分校的ACE项目代表。Wofsy博士和Blustone博士将加入他们的领导团队 医学部临床试验中心主任Maria Dall‘Era博士的作用 我们的大部分临床试验。Wofsy Blustone博士和Dall‘Era博士将协助履行他们的职责 作者：Venecia Jacobs。雅各布斯女士一直担任我们ACE计划的赠款经理 因此，她非常熟悉管理这个复杂程序的错综复杂的情况。 Wofsy博士和Blustone博士特别有资格领导ACE项目，因为他们两人 真正弥合了自身免疫性疾病基础研究和临床研究之间的差距。Wofsy博士致力于 他在职业生涯的前二十年致力于系统性红斑狼疮小鼠模型的新治疗策略的研究 红斑狼疮(SLE)，在将他的研究重点转向临床的设计和实施之前 里亚尔适用于系统性红斑狼疮患者。他已经证明了他有能力将老鼠模型中有前途的工作翻译成 通过领导几项主要试验，最引人注目的是联合试验，将系统性红斑狼疮转化为多中心协作临床试验 ACE/ITN对CTLA4lg的试验源于他之前的基于实验室的研究。同样，蓝石博士也有 成功地将他在糖尿病小鼠模型中的工作带入了治疗糖尿病的大型多中心新疗法试验 糖尿病患者。因此，沃夫西博士和蓝石博士不仅非常适合管理方面的工作 领导这个项目，但他们也有资格为其他调查人员提供科学指导 他的计划。

The Administrative Unit for the proposed UCSF Autoimmunity Center of Excellence (ACE) consists of personnel who have extensive experience in the administration of NIH Center grants. The principal investigator, Dr. David Wofsy, has served as PI for the UCSF ACE grant during the current cycle; prior to that, he served for 10 years as PI for the UCSF Multipurpose Arthritis and Musculoskeletal Diseases Center (MAMDC) grant through NIAMS. Thus, he is very experienced in the leadership of multi-project NIH programs. Dr. Wofsy will be responsible for oversight of the UCSF Center and will serve as the clinical research representative from UCSF to the ACE program. Dr. Jeffrey Bluestone, co-Pi for the Administrative Unit, also has extensive experience in the administration of complex program grants, as evidenced by his role as Director of the NIAID Immune Tolerance Network. Dr. Bluestone will serve as the basic research representative from UCSF to the ACE program. Drs. Wofsy and Bluestone will be joined in their leadership roles by Dr. Maria Dall'Era, Director of the Department of Medicine Clinical Trials Center which will house most of our clinical trials. Drs. Wofsy Bluestone, and Dall'Era will be assisted in fulfilling their responsibilities by Venecia Jacobs. Ms. Jacobs has served as grants manager for our ACE program throughout the current cycle, so she is very familiar with the intricacies of administering this complex program. Drs. Wofsy and Bluestone are particularly well-qualified to lead an ACE program, in that both of them genuinely bridge the gap between basic and clinical research in autoimmune diseases. Dr. Wofsy devoted he first two decades of his career to studies of new therapeutic strategies in murine models for systemic upus erythematosus (SLE), before shifting the emphasis of his research to the design and conduct of clinical rials for people with SLE. He has demonstrated his ability to translate promising work in murine models for SLE into multicenter collaborative clinical trials in humans by leading several major trials, most notably a joint ACE/ITN trial of CTLA4lg that arose out of his prior laboratory-based research. Similarly, Dr. Bluestone has successfully carried his work in murine models for diabetes into large multicenter trials of new therapies for people with diabetes. Drs. Wofsy and Bluestone are thus not only well-suited to the administrative aspects of leading this program, but they are also well-qualified to provide scientific guidance to other investigators in his program.